Sugi Predict

Sugi Predict / Compounds / SCHEMBL1711383

SCHEMBL1711383

SCHEMBL1711383

NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)OCc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ NMBR P28336 2/20 0.73
▸ MAPT P10636 2/20 0.69
▸ GAA P10253 1/20 0.69
▸ HTT P42858 1/20 0.69
▸ MMP2 P08253 11/20 0.69
▸ MMP9 P14780 11/20 0.69
▸ MMP8 P22894 11/20 0.69
▸ MMP14 P50281 11/20 0.69
▸ LMNA P02545 1/20 0.67
▸ MMP11 P24347 2/20 0.66
▸ ECE1 P42892 1/20 0.65
▸ MMP7 P09237 1/20 0.65
▸ CA2 P00918 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29472048 1.00 NMBR (0.73) NMBRMAPTGAAHTTMMP2
SCHEMBL5381814 1.00 NMBR (0.73) NMBRMAPTGAAHTTMMP2
SCHEMBL5556658 0.96 NMBR (0.74) NMBRMAPTGAAHTTMMP2
SCHEMBL5399966 0.94 NMBR (0.71) NMBRMAPTGAAHTTMMP2
SCHEMBL3808330 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA
SCHEMBL3265534 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA
SCHEMBL29401760 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA
SCHEMBL1285921 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA
SCHEMBL29935468 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA
SCHEMBL29386277 0.91 NMBR (0.76) NMBRMAPTGAAHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365052-B1 pH tuneable-gellant for use in consumer product compositions PROCTER & GAMBLE (US) 2016-07-13 — — EP disclosed
US-9150510-B2 Amino acid derivative NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2015-10-06 — — US disclosed
EP-2345635-A1 AMINO ACID DERIVATIVE Nippon Zoki Pharmaceutical Co., Ltd. (JP) 2011-07-20 — — EP disclosed
US-20110172442-A1 AMINO ACID DERIVATIVE NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 2011-07-14 — — US disclosed
US-20070111930-A1 PROCESS FOR PREPARING VAPREOTIDE DR. REDDY'S LABORATORIES, INC. 2007-05-17 — — US disclosed
US-20070111930-A1 PROCESS FOR PREPARING VAPREOTIDE DR. REDDY'S LABORATORIES, INC. 2007-05-17 — — US disclosed
US-20070112008-A1 Saframycins, analogues and uses thereof MYERS ANDREW G 2007-05-17 — — US disclosed
US-7163671-B2 Long-term stabilized formulations CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-01-16 — — US disclosed
US-20030092622-A1 Preparation stabilized over long time CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-05-15 — — US disclosed
EP-1260230-A1 PREPARATIONS STABILIZED OVER LONG TIME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-11-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172442-A1 AMINO ACID DERIVATIVE OPRL1, OPRK1, SLC1A1 NMBR 327/4885MAPT 1855/4885GAA 3310/4885
US-20070112008-A1 Saframycins, analogues and uses thereof MYC, MAN1B1, MRPS18A NMBR 1181/4885MAPT 3660/4885GAA 61/4885
US-20070111930-A1 PROCESS FOR PREPARING VAPREOTIDE VIP, SSTR4, SSTR5 NMBR 565/4885MAPT 3667/4885GAA 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.